LOGIN  |  REGISTER
Astria Therapeutics
C4 Therapeutics

Inari Medical Files Patent Infringement Lawsuit Against Imperative Care and Truvic Medical

May 23, 2024 | Last Trade: US$43.47 1.39 -3.10

IRVINE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it had filed a patent infringement lawsuit against Imperative Care, Inc. and Truvic Medical, Inc. (collectively, “Truvic”). The suit was filed in the United States District Court for the Northern District of California. Inari is seeking injunctive relief and damages for infringement.

Inari believes Truvic is infringing eight of Inari Medical’s patents for the use of aspiration-based thrombectomy devices to treat pulmonary emboli and deep vein thrombosis. Truvic products named in the suit include the Symphony Thrombectomy System.

“Inari was founded to improve patients’ lives using purpose-built innovation. Our mission depends on these innovations, and we are deeply committed to protecting our intellectual property rights,” said Drew Hykes, CEO of Inari Medical.

About Inari Medical, Inc.

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous and other diseases. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.

Investor Contact:
John Hsu, CFA
VP, Investor Relations
949-658-3889
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB